Intensity Therapeutics, Inc. (INTS)
Nasdaq: INTS · Biological Products, (No Diagnostic Substances) · Shelton, CT · filing with the SEC since 2013
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Mar 27, 2026 | Mar 13, 2025 | Mar 14, 2024 | · |
| Research and development | 6,785,000 | 10,496,000 | 4,786,000 | 5,132,000 |
| General and administrative | 5,187,000 | 6,089,000 | 3,533,000 | 2,418,000 |
| Total operating expenses | 11,972,000 | 16,585,000 | 8,319,000 | 7,550,000 |
| Operating income | -11,972,000 | -16,585,000 | -8,319,000 | -7,550,000 |
| Interest expense | · | 0 | 305,000 | 82,000 |
| Interest and investment income | 180,000 | 314,000 | 324,000 | 2,000 |
| Other income (expense), net | 186,000 | 3,000 | · | · |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income | -11,606,000 | -16,268,000 | -10,538,000 | -7,582,000 |
| Preferred dividends | · | 0 | 1,324,000 | 0 |
| Earnings per share, basic | -8.56 | -29.24r | -34.50b | -55.50b |
| Earnings per share, diluted | -8.56 | -29.24r | -34.50b | -55.50b |
| Weighted average shares, basic | 1,356,358 | 556,279r | 344,653b | 136,404b |
| Weighted average shares, diluted | 1,356,358 | 556,279r | 344,653b | 136,404b |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-25 reverse split of Feb 2026.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossPreferred dividends paid to preferred holders before common shareholders
us-gaap:PreferredStockDividendsIncomeStatementImpactEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding